Biomarin Pharmaceutical Inc (BMRN)

Debt-to-assets ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	593,605	593,095	592,586	1,084,990	1,084,010	1,083,020	1,082,030	1,081,050	1,080,060	1,079,080	1,078,090	1,077,110	1,076,130	1,075,140	1,074,160	1,073,200	486,713	486,238	843,616	839,165
Total assets	US$ in thousands	6,872,670	6,841,600	6,758,160	6,563,170	6,433,700	6,375,070	6,264,040	6,145,840	6,062,710	6,004,770	5,977,480	5,898,500	5,805,050	5,848,020	6,158,090	5,302,110	4,722,840	4,690,040	4,558,130	4,393,380
Debt-to-assets ratio		0.09	0.09	0.09	0.17	0.17	0.17	0.17	0.18	0.18	0.18	0.18	0.18	0.19	0.18	0.17	0.20	0.10	0.10	0.19	0.19

March 31, 2024 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $593,605K ÷ $6,872,670K
= 0.09

The debt-to-assets ratio of Biomarin Pharmaceutical Inc has remained relatively stable over the past few quarters, ranging between 0.09 and 0.20. This ratio measures the proportion of the company's assets that are financed by debt, and a lower ratio typically indicates lower financial risk and a stronger financial position.

In general, Biomarin Pharmaceutical Inc has maintained a conservative level of debt relative to its total assets, which suggests a prudent financial management approach. The slight increase in the ratio from 0.09 to 0.20 in the first quarter of 2020 may indicate a temporary increase in debt levels or a decrease in asset values during that period.

Overall, the consistent trend of the debt-to-assets ratio hovering around the 0.10 to 0.20 range indicates that Biomarin Pharmaceutical Inc has been managing its debt obligations in a way that aligns with its overall financial strategy and risk tolerance levels.